Trastuzumab and breast cancer: developments and current status. - Wikidata - wikimedia - TriplyDB

Trastuzumab and breast cancer: developments and current status.

Trastuzumab and breast cancer: developments and current status.

http://www.wikidata.org/entity/Q36540576

about

Comprehensive analysis of the factors contributing to the stability and solubility of autonomous human VH domains HER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients.HER-2 overexpression and survival in colorectal cancer: a meta-analysis Near infrared fluorescent optical imaging for nodal staging.An interdisciplinary and collaborative initiative in palliative care research.Pancreatic endocrine tumours: mutational and immunohistochemical survey of protein kinases reveals alterations in targetable kinases in cancer cell lines and rare primaries Growth factor-induced resistance to tamoxifen is associated with a mutation of estrogen receptor alpha and its phosphorylation at serine 305.Fluorescence lifetime imaging system for in vivo studies Induction of caspase-dependent extrinsic apoptosis by apigenin through inhibition of signal transducer and activator of transcription 3 (STAT3) signalling in HER2-overexpressing BT-474 breast cancer cells.Breast cancer: assessing response to neoadjuvant chemotherapy by using US-guided near-infrared tomography.Trastuzumab therapy vs tetracycline controlled ERBB2 downregulation: influence on tumour development in an ERBB2-dependent mouse tumour model Monitoring therapeutic response of human ovarian cancer to 17-DMAG by noninvasive PET imaging with (64)Cu-DOTA-trastuzumab.Molecular imaging as a tool for personalized and targeted anticancer therapy.Targeting HER proteins in cancer therapy and the role of the non-target HER3.Quercetin induces caspase-dependent extrinsic apoptosis through inhibition of signal transducer and activator of transcription 3 signaling in HER2-overexpressing BT-474 breast cancer cells.Using in-vivo fluorescence imaging in personalized cancer diagnostics and therapy, an image and treat paradigm.Strategies to optimize the use of targeted agents for tumor therapy.Labeling and Biological Evaluation of (99m)Tc-HYNIC-Trastuzumab as a Potential Radiopharmaceutical for In Vivo Evaluation of HER2 Expression in Breast Cancer.Survival is associated with complete response on MRI after neoadjuvant chemotherapy in ER-positive HER2-negative breast cancer Infectious complications associated with monoclonal antibodies and related small molecules [(64) Cu]-labelled trastuzumab: optimisation of labelling by DOTA and NODAGA conjugation and initial evaluation in mice.Trastuzumab in the management of early and advanced stage breast cancer.Human epidermal growth factor receptor dimerization analysis in breast cancer diagnosis: potential for improving testing accuracy and treatment selection.Assessment of free dye in solutions of dual-labeled antibody conjugates for in vivo molecular imaging.Stiffness of tumours measured by shear-wave elastography correlated with subtypes of breast cancer.Trastuzumab labeled to high specific activity with ¹¹¹In by conjugation to G4 PAMAM dendrimers derivatized with multiple DTPA chelators exhibits increased cytotoxic potency on HER2-positive breast cancer cells.Inhibition of phosphoinositide 3-kinase enhances the cytotoxicity of AG1478, an epidermal growth factor receptor inhibitor, in breast cancer cells.Apigenin induces apoptosis via extrinsic pathway, inducing p53 and inhibiting STAT3 and NFκB signaling in HER2-overexpressing breast cancer cells.Imaging and biodistribution of Her2/neu expression in non-small cell lung cancer xenografts with Cu-labeled trastuzumab PET.Immunonanoparticles--an effective tool to impair harmful proteolysis in invasive breast tumor cells.NK cell-mediated antibody-dependent cellular cytotoxicity is enhanced by tamoxifen in HER2/neu non-amplified, but not HER2/neu-amplified, breast cancer cells.Assessment of bevacizumab conjugated to Cy5.5 for detection of head and neck cancer xenografts.Overexpression of metadherin/MTDH is associated with an aggressive phenotype and a poor prognosis in invasive breast cancer.

P2860

Q27649162-0CF4DCB8-DB61-4C1C-B60C-B0541109EE98 Q33305210-64E02C32-01AB-460B-AA30-90006C521DBF Q33979049-91E8E90F-CA38-4E10-9DA1-E762C71EBBB2 Q34038991-13D8E051-CD5C-4B35-AFF7-8A60D12F9A58 Q34418241-412C279C-E6A0-4872-9E0A-5327DF1AABE5 Q35747269-A74145BB-732E-4E6C-8873-7354FBBCE4B6 Q35786706-ADCB2AC7-2459-4DC8-837B-9F14BCCBA2EF Q36439951-C35D31BF-416F-4B4F-B35A-37CE10ED2C68 Q36450288-F6FB434B-13B7-47EC-94AD-F60FE0CC170C Q36573411-51C83047-7D79-40FB-B636-88946128A925 Q36667406-514CCB21-56FC-441B-8639-C4FE37C5942F Q36680209-A47F0D64-AF5F-4049-8A10-C328AF5D9F15 Q36752665-AA27D2AF-53BD-480D-A160-153F29BF3E56 Q36898642-502E1087-169C-4235-86D1-6798CE40F760 Q36983821-3BB37254-ADD2-4EA4-8D01-682CD59CCA32 Q37031461-E7BD0547-2A82-484C-B5A9-961745A367D5 Q37060553-34064A52-2AFB-4321-BDAA-2B8547F8BCC9 Q37100372-D1900D2E-2FF8-46FB-9DC3-0CF27A04EE5F Q37156474-B720FFBF-93B5-499F-9991-DC097A27A127 Q37156636-27D418C0-E22A-4899-A018-AF487B9D9083 Q37268891-A36110C6-E65D-4734-B1B1-A74EC784EBD3 Q37290613-1B56AED6-91A1-4A0A-8751-2F1250824ABF Q37635099-D1BD1D08-3272-41FD-96D7-5833EDCB429A Q37645745-1D8CD620-E679-4FB4-8AFE-06F358616598 Q38106851-247B57D5-2B8B-46D2-B184-82499E8BD387 Q39161020-40EBDBB8-F04C-4A59-85FF-ABEEF6A5421C Q39325988-3A4A8897-761B-474F-B788-02BC6470271A Q39360179-7621D3A5-CFBA-44CF-BC94-3D24EF722613 Q39729571-642D9EA5-A772-4588-894C-99FE875F2FAF Q40100919-FCFA71D7-CF97-4018-8837-8AC8E83B703B Q51543249-A2DB8882-3879-4F44-9B83-E6DD4EFFAB16 Q53504951-8CCDB955-DFFA-4AB9-A518-A8B36ACF2879 Q54296166-D27966A1-C65F-493E-9132-8747F5EBBA08

P2860

Trastuzumab and breast cancer: developments and current status.

http://www.wikidata.org/entity/Q36540576

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

Trastuzumab and breast cancer: developments and current status.

@ast

Trastuzumab and breast cancer: developments and current status.

@en

type

label

Trastuzumab and breast cancer: developments and current status.

@ast

Trastuzumab and breast cancer: developments and current status.

@en

prefLabel

Trastuzumab and breast cancer: developments and current status.

@ast

Trastuzumab and breast cancer: developments and current status.

@en

P1433

Q36540576-7349BB11-B4CE-4306-81A0-487375B53945

P1476

Q36540576-C511D4F9-92D6-48FA-9C5B-641629C050B9

P2093

Q36540576-0793C5E3-6F61-4420-92CF-6451CC3C4012

Q36540576-07EEA6AC-01A7-469F-923F-DA0FCE690DA2

Q36540576-0EFBDFAC-3E04-4133-B394-750378B1A6C1

Q36540576-320FFE65-46E1-48F0-ABDB-7211420C107B

Q36540576-48F2A524-331C-42F5-B892-49A84CD69A35

Q36540576-A1DC6EC7-5A03-4CE1-B69A-88839EAC3CBA

Q36540576-B502CF3E-90B6-419D-8A36-0E95B94D7F36

P2860

Q36540576-470D466C-A82F-4012-86EF-CDE3E9AF88E9

Q36540576-5DABEDE4-93E2-4629-9337-DF926DAE9E8A

P2888

Q36540576-A0ACEC1F-1EF7-462D-A585-3428F3FF706F

P304

Q36540576-CFC91A5F-1694-4173-85E0-A8D6BA9295B8

P31

Q36540576-46994E0A-A4D9-4727-B403-692383C40FB2

P356

Q36540576-D9461AE6-7CD9-4AC6-A7B0-5D7337C308D7

P433

Q36540576-7D4EB05C-1653-453F-81C7-F795C16DB5A0

P478

Q36540576-AD972C63-A4CD-4675-AF20-C995D129AA4B

P50

Q36540576-5653C137-448B-40C9-9E0E-4B6401B729E2

P577

Q36540576-633870FF-C6F4-4667-849D-686CEBA48A6C

P698

Q36540576-674793D0-EC03-4F7C-AA30-36AC2E964D5C

P356

S10147-006-0575-4

P1433

International Journal of Clinical Oncology

P1476

Trastuzumab and breast cancer: developments and current status.

@en

P2093

Akinori Egashira

http://www.w3.org/2001/XMLSchema#string

Eiji Oki

http://www.w3.org/2001/XMLSchema#string

Eriko Tokunaga

http://www.w3.org/2001/XMLSchema#string

Kojiro Nishida

http://www.w3.org/2001/XMLSchema#string

Masaru Morita

http://www.w3.org/2001/XMLSchema#string

Tadashi Koga

http://www.w3.org/2001/XMLSchema#string

Yoshihiro Kakeji

http://www.w3.org/2001/XMLSchema#string

P2860

High efficacy of gemcitabine and cisplatin plus trastuzumab in patients with HER2-overexpressing metastatic breast cancer: a phase II study.

p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor.

P2888

s10147-006-0575-4

P304

199-208

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10147-006-0575-4

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

Yoshihiko Maehara

P577

2006-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16850126

http://www.w3.org/2001/XMLSchema#string